MARKET

CTIC

CTIC

Cti Biopharma
NASDAQ
5.64
+0.08
+1.44%
After Hours: 5.56 -0.08 -1.42% 18:04 12/08 EST
OPEN
5.55
PREV CLOSE
5.56
HIGH
5.73
LOW
5.43
VOLUME
1.73M
TURNOVER
0
52 WEEK HIGH
7.80
52 WEEK LOW
1.740
MARKET CAP
715.68M
P/E (TTM)
-5.1905
1D
5D
1M
3M
1Y
5Y
Looking Into CTI BioPharma's Return On Capital Employed
Benzinga · 11/30 14:46
CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET. The conference will be held in a virtual meeting format.
PR Newswire · 11/30 12:00
Insider Sell: Cti Biopharma
Insider Sell: Cti Biopharma
MT Newswires · 11/14 17:00
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09 10:08
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
Benzinga · 11/09 07:53
CTI BioPharma to Present at Upcoming November Conferences
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.
PR Newswire · 11/08 21:05
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08 17:51
CTI Biopharma surges 17% higher on Q3 earnings beat
Seekingalpha · 11/08 17:47
More
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, IRAK1, FLT3 and CSF1R for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3 and CSF1R.

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.